epigenetics
(11)
K36 Therapeutics, Inc.
K36 Therapeutics is a Cambridge, Massachusetts clinical-stage biotech developing first-in-class oral small-molecule inhibitors of NSD2/MMSET, an epigenetic enzyme that drives hard-to-treat cancers. Its lead candidate, gintemetostat (KTX-1001), is in Phase 1 for relapsed/refractory multiple myeloma carrying the t(4;14) translocation, and a second program, KTX-2001, targets metastatic castration-resistant prostate cancer. Backed by Atlas Venture, F-Prime Capital, Eight Roads Ventures, Nextech Invest and Bristol Myers Squibb, K36 has raised roughly $100M+ to translate chromatin biology into precision cancer medicines.
Apostle Inc
Apostle Inc is a Pleasanton, California biotechnology company that develops nucleic acid isolation and preservation technologies for liquid biopsy. Its flagship magnetic-nanoparticle kit, Apostle MiniMax, extracts circulating cell-free DNA and RNA from blood for applications in early cancer detection, non-invasive prenatal testing, infectious disease research, and even astronaut biospecimen collection in commercial spaceflight. Founded in 2018 out of the Stanford StartX accelerator, the company sells reagents, automation instruments, and CLIA/CAP lab services to researchers and diagnostics developers worldwide.
Aqtual, Inc.
Aqtual, Inc. is a Hayward, California precision medicine company that reads epigenetics, gene regulation and transcriptomics from a single blood draw. Its proprietary active-chromatin cell-free DNA (cfDNA) platform captures circulating chromatin to survey hundreds of thousands of regulatory sites, integrating DNA, epigenetic regulation and protein-DNA binding in one blood-based assay. The company is first commercializing a test that predicts which therapy will work for rheumatoid arthritis patients, with a broader pipeline spanning oncology, immunology, cardiovascular, metabolic and neurological disease. Aqtual has raised roughly $47M to date, including a $31M Series B in July 2025.
ARNA Genomics US Inc.
ARNA Genomics US Inc. is a San Francisco-based biotechnology company developing multiomics liquid-biopsy technology for early cancer detection. Its lead assay, ARNA Breast, analyzes cell-free DNA and plasma enzyme activity from a routine blood draw to flag early-stage breast cancer, with proof-of-concept studies reporting sensitivity above 90%. Founded in 2013 and led by CEO Egor Melnikov, the company raised a $3.5M Series A in 2020 to fund clinical validation.
ibelong
ibelong is a San Francisco-based consultancy that helps organizations build inclusive, resonant workplace cultures using a neurochemical framework grounded in affective neuroscience, relational neurobiology and epigenetics. Led by CEO and epigenetic coach Rajkumari Neogy, the company translates the brain science of trust and belonging into practical programs - immersive courses, leadership coaching, compassion circles and layoff (RIF) support - aimed at reducing conflict, burnout and turnover. Formerly known as iRestart, ibelong has worked with leaders at more than 175 startups and enterprises.
Syntax Bio
Syntax Bio is a Chicago synthetic biology company building Cellgorithm, a CRISPR-based platform that programs stem cells to differentiate on command. Instead of coaxing stem cells into specialized cell types through months of manual, growth-factor-heavy protocols, Cellgorithm encodes the sequence of gene activations that mimic human development into a single DNA program, collapsing timelines from months to weeks. Spun out of the University of Illinois Chicago and formerly known as Cellgorithmics, the company has raised more than $25 million and is advancing a pancreatic beta cell therapy for type 1 diabetes while partnering with biopharma to program cells at scale.
ACTIVZ
ACTIVZ is a West Jordan, Utah-based health and wellness company that bills itself as the first direct-selling brand built around epigenetics - the idea that lifestyle and nutrition can influence how genes express themselves. Founded in 2017 by David Brown and Ryan Thompson, the company sells supplements (LINQ, AIRO, Optimend) and an anti-aging skincare line through a distributor network paired with an omnichannel e-commerce model. It launched first in Spanish-speaking Mexico before expanding to the US, Peru, Japan and beyond.
Generation Lab
Generation Lab is a San Francisco longevity biotech building SystemAge, a diagnostic that measures how fast your body is actually aging rather than predicting a number. Using DNA methylation analysis of hundreds of biomarkers, it reports biological ages across roughly 19 organ systems from a blood sample, then hands clinicians an actionable plan to track whether interventions are moving the needle. Founded in 2023 by CEO Alina Rui Su, UC Berkeley aging researcher Dr. Irina Conboy, and operator Michael Suswal, the company raised an $11M seed in October 2025 led by Accel and works with 275+ clinics across roughly 18 countries.
Tune Therapeutics
Tune Therapeutics is a genetic-medicine company building tools to turn genes up or down without cutting DNA. Its TEMPO epigenetic-editing platform tunes gene expression the way a sound engineer rides a fader - reversible, programmable, and precise. Spun out of Duke's Gersbach Lab, Tune raised over $175M in Series B financing in January 2025 and is running first-in-human trials of TUNE-401, an epigenetic silencer for chronic hepatitis B, with the larger ambition of editing the genome's software to extend human healthspan.
Elysium Health
Elysium Health is a New York-based cellular health company that turns peer-reviewed aging research into consumer products. Founded in 2014 by entrepreneur Eric Marcotulli, operator Dan Alminana, and MIT aging biologist Leonard Guarente, it pairs a scientific advisory board stacked with Nobel laureates with a direct-to-consumer model. Its flagship supplement Basis raises NAD+ levels tied to cellular energy, and its Index test estimates biological age from a saliva sample using epigenetic methylation analysis.
Moonwalk Biosciences
Moonwalk Biosciences is a San Francisco Bay Area biotech building precision epigenetic medicines. Co-founded by former Illumina CTO Alex Aravanis and CRISPR pioneer Feng Zhang, the company pairs whole-genome, single-cell epigenome mapping with AI-guided 'read-and-write' epigenetic editing tools that reprogram cells to a healthy state without cutting or altering the underlying DNA. Launched out of stealth in January 2024 with $57 million in seed and Series A funding, Moonwalk aims to file its first IND within a few years.